FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine. Capsule containing an inhalable powder composition containing 75 wt. % or more of levodopa, dipalmitoylphosphatidylcholine (DPPC) and salt. Powder is characterised by a working density of less than 100 g/l. Described is a capsule containing an inhalable powder composition containing 75 wt. % or more of levodopa, dipalmitoylphosphatidylcholine (DPPC) and salt, the powder is characterised by a working density of less than about 100 g/l, and wherein the capsule shell contains hydroxypropyl methylcellulose (HPMC) and titanium dioxide.
EFFECT: capsule provides the release of a larger amount of powder compared to the amount of powder released from capsules that do not contain titanium dioxide as capsule material.
18 cl, 6 dwg, 26 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ULTRA LOW DENSITY INHALATION POWDERS | 2013 |
|
RU2670987C2 |
| REDUCTION OF INPATIENT VARIABILITY OF LEVODOPA CONCENTRATIONS IN BLOOD PLASMA | 2013 |
|
RU2682681C2 |
| LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | 2013 |
|
RU2685718C2 |
| RAPID REDUCTION OF MOTOR FLUCTUATIONS ACCOMPANYING PARKINSON'S DISEASE | 2014 |
|
RU2698330C2 |
| DRY POWDER FORMULATIONS AND METHODS OF TREATING PULMONARY DISEASES | 2010 |
|
RU2577698C2 |
| CATIONS OF MONOVALENT METALS OF DRY POWDERS FOR INHALATIONS | 2011 |
|
RU2640921C2 |
| INHALATION COMPOSITIONS CONTAINING MONTELEUKAST ACID AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID | 2008 |
|
RU2470639C2 |
| INTRAPULMONARY ADMINISTRATION OF FUOROQUINOLONE | 2009 |
|
RU2497524C2 |
| ANTIFUNGAL DRY POWDERS | 2017 |
|
RU2766086C2 |
| METHODS OF TREATING FUNGAL INFECTIONS | 2019 |
|
RU2820457C2 |
